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Background: The prevalence of severe and complex obesity is increasing worldwide and surgery may offer an
effective and lasting treatment. Laparoscopic adjustable gastric band and Roux-en-Y gastric bypass surgery are the
two main surgical procedures performed.
Design: This open parallel-group randomised controlled trial will compare the effectiveness, cost-effectiveness and
acceptability of gastric band (Band) versus gastric bypass (Bypass) in adults with severe and complex obesity. It has
an internal pilot phase (in two centres) with integrated qualitative research to establish effective and optimal
methods for recruitment. Adults with a body mass index (BMI) of 40 kg/m2 or more, or a BMI of 35 kg/m2 or more
and other co-morbidities will be recruited. At the end of the internal pilot the study will expand into more centres
if the pre-set progression criteria of numbers and rates of eligible patients screened and randomised are met and if
the expected rates of retention and adherence to treatment allocation are achieved. The trial will test the joint
hypotheses that Bypass is non-inferior to Band with respect to more than 50% excess weight loss and that Bypass
is superior to Band with respect to health related quality of life (HRQOL, EQ-5D) at three years. Secondary outcomes
include other weight loss measures, waist circumference and remission/resolution of co-morbidities; generic and
symptom-specific HRQOL; nutritional blood test results; resource use; eating behaviours and adverse events. A core
outcome set for reporting the results of obesity surgery will be developed and a systematic review of the evidence
for sleeve gastrectomy undertaken to inform the main study design.
Discussion: By-Band is the first pragmatic study to compare the two most commonly performed bariatric surgical
procedures for severe and complex obesity. The design will enable and empower surgeons to learn to recruit and
participate in a randomised study. Early evidence shows that timely recruitment is possible.
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The prevalence of obesity in adults is increasing around
the world. In the United Kingdom (UK) rates have trebled
during the past 25 years to around 24% [1]. If trends per-
sist, 36% of men and 28% of women aged 21 to 60 will be
obese in 2015, and worldwide approximately 700 million
adults will be living with the condition [1-3]. The preva-
lence of complex obesity (clinically defined as a body mass
index (BMI) of 35 kg/m2 or more with co-morbidity or a
BMI over 40 kg/m2 without co-morbidity) is also on the
increase, and the UK prevalence has been estimated at
around 2.1% [4,5]. Obesity is associated with a number of
health problems, including type-2 diabetes, cardiovascular
disease, musculoskeletal disorders, infertility, and psychi-
atric disorders. The mortality rate for those with complex
obesity is more than double that for the general popula-
tion [6]. Additionally, obesity is an intermediary to social
inequalities in health [7] and places a huge financial bur-
den on the National Health Service (NHS). The direct
costs of treating diseases associated with being overweight
and obesity were estimated at £3.2 billion in 2002, or
nearly 5% of total NHS expenditure [8]. On an individual
level, living with obesity has been associated with psycho-
logical distress and social stigma, both of which may have
a significant impact on individuals’ quality of life [9,10].
The prevention and treatment of obesity is thus a key
priority for the NHS, and the provision of weight man-
agement services for adults is now firmly established as
a core policy objective.
Reversal of obesity is uncommon without intervention
[11], and the National Institute for Health and Care Ex-
cellence (NICE) guidance states that health authorities
should establish comprehensive care pathways for ad-
dressing being overweight and obesity within their popula-
tions, which should include access to diet and exercise
interventions, anti-obesity drugs, and in some circum-
stances weight reduction surgery [12]. However, it is
known that many interventions for obesity fail and bariat-
ric surgery is increasingly being viewed as a solution to
weight loss, particularly for those with complex obesity.
Although surgery is usually considered after patients have
attempted other forms of weight loss without success, the
exception to this is for adults with a BMI > 50. NICE
guidelines recommend surgery as a first-line option for
this group of patients (instead of lifestyle interventions or
drug treatment) if surgical intervention is considered ap-
propriate. Surgical procedures for those with obesity aim
to bring about a sustained reduction in weight through re-
striction of intake, malabsorption of food and/or hormonal
influence. There are several different operations in use in-
cluding laparoscopic Roux-en-Y laparoscopic gastric by-
pass (Bypass), laparoscopic adjustable gastric band (Band),
biliopancreatic diversion and its duodenal switch variant,
vertical banded gastroplasty and sleeve gastrectomy.Despite the variety of different surgical procedures
available, the two most commonly performed operations
worldwide for many years have been gastric Bypass and
gastric Band. At the time the By-Band study was conceived
and set-up, these two procedures together accounted
for approximately 80% of all obesity operations in the
UK and the United States [13,14]. A gastric Bypass
involves restricting the volume of food which can be
eaten by creating a small thumb-sized pouch from the
upper stomach and a bypass of the remaining stom-
ach. Bypass alters physiology and anatomy in such a
way as to achieve early and generally rapid weight loss
but has risks of serious early morbidity and, rarely,
death [15,16]. Longer term complications may include
the need for re-operation because of the development
of internal hernias or intestinal obstruction and nutri-
tional deficiencies. A gastric Band is an inflatable sili-
cone device which is placed around the top portion of
the stomach to create a smaller stomach pouch. The
Band also achieves weight loss, but this is generally
more gradual. Short term surgical risks of a Band are
very uncommon [15] but longer term complications
include band erosion or migration, pouch dilatation,
leakage from the circuit or infection which may re-
quire revision surgery or band removal [16,17]. Over
the past three years, interest in sleeve gastrectomy has
increased significantly and indeed recent UK individ-
ual surgeon data shows that rates of sleeve gastrec-
tomy have now surpassed those of gastric Band in the
NHS [18]. Data from a worldwide survey show similar
patterns of change [19]. Sleeve gastrectomy reduces
the stomach to about 25% of its original size, remov-
ing a large portion of the stomach along the greater
curvature, leaving a sleeve or tube-like structure.
Complications include sleeve leakage, blood clots and
infections, nausea and vomiting.
Evidence for the different types of surgery has been
summarised [11] and updated. There were 20 randomised
controlled trials (RCTs) identified in the review that com-
pared different types and variations of bariatric surgery,
with only one comparing gastric Band with gastric Bypass.
The latter single centre trial in Italy included 51 partici-
pants, excluded some after randomisation, did not analyse
the data according to the intention-to-treat principle, did
not blind outcome assessors and did not assess health-
related quality of life (HRQOL) [20,21]. By updating this
review, we identified another six trials comparing different
bariatric procedures and one further trial of gastric Band
and Bypass surgery [22]. This study randomised 250 pa-
tients, but differentially excluded some after randomisa-
tion creating imbalance in the numbers in each group and
an imbalance in key patient characteristics at baseline (age
and BMI) and the analysis was not by intention-to-treat
[22]. The generation of the allocation sequence was
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and no details of the number of participants completing
HRQOL questionnaires. The evidence of the relative ef-
fectiveness of Band and Bypass is, therefore, inadequate
with just two single centre trials that have an uncertain
risk of bias and inadequate data characterising HRQOL.
The availability and choice of bariatric surgical practice
is consequently based on the preferences of local com-
missioners, surgeons and patients and there remains
an urgent need for a well-designed RCT with clinically
relevant comparisons, measures of generic and disease
specific HRQOL, cost-effectiveness evaluations and at
least medium term follow-up and documentation of
longer term adverse events. This need was highlighted
in the systematic review, but it was also stated that a
trial of gastric Band versus Bypass may be too difficult
to conduct and recruit into because of strong prefer-
ences amongst surgeons that influence patient selec-
tion for surgery [11]. The By-Band study (funded in
2011), therefore was designed to compare the two most
commonly performed bariatric operations at that time
(gastric Band and gastric Bypass). It was designed in
two phases so that the barriers to effective recruitment
could be overcome within the first phase (an internal
pilot), before extending into the main trial (Phase 2). A
review of the literature and of current UK practice
regarding sleeve gastrectomy will also be undertaken
in Phase 1 to understand whether uptake and stand-
ardisation of the procedure is sufficient to extend the
study in Phase 2 to include a third treatment arm.
Methods/Design
Aims and objectives
The By-Band study will compare the effectiveness,
cost-effectiveness and acceptability of Band versus By-
pass surgery for treatment of complex obesity. We will
test the joint hypotheses that (a) Bypass is non-inferior
to Band with respect to excess weight loss of more
than 50% at three years and that (b) Bypass is superior
to Band with respect to HRQOL at three years. In the
primary analysis, both outcomes will be considered
collectively, that is both hypotheses must be supported
to conclude that Bypass is more effective than Band.
Specific objectives are to estimate:
1. The difference between groups in the proportion of
patients achieving > 50% excess weight loss at three
years;
2. The difference between groups in their average
EQ-5D health state score [23] at three years;
3. The difference between groups with respect to a
range of secondary outcomes;
4. The cost-effectiveness of gastric Band and gastric
Bypass.Study design
By-Band is a pragmatic RCT with two phases.
Phase 1 will establish whether it is possible to recruit
into this surgical trial using integrated qualitative methods
in two centres. It will develop of a core outcome set to as-
sess the benefits and adverse events of obesity surgery and
undertake a literature review and review of current prac-
tice of sleeve gastrectomy. Progression to Phase 2 will
depend upon the results of these initiatives and will be
reviewed with the Trial Steering Committee (TSC) and
the funder, National Institute for Health Research Health
Technology Assessment Programme (NIHR-HTA).
Phase 2 will extend recruitment to up to six additional
centres, using the optimum methods of recruitment estab-
lished in Phase 1. The overall schema for the trial is shown
in Figure 1.Research approval
Research ethics approval was granted by the South West -
Frenchay Research Ethics Committee (reference 11/SW/
0248) in December 2011.Study population
All patients referred for bariatric surgery will form the
target population and be screened for trial eligibility.
Male and female patients > 18 years of age referred for
bariatric surgery according to NICE guidelines (BMI of
40 kg/m2 or more, or BMI of 35 kg/m2 or more and
other co-morbidities that could improve with weight
loss), who are fit for anaesthesia and surgery, committed
to follow-up and who provide written informed consent
will be eligible. Ineligible will be participants with, i) a
history of previous gastric surgery, ii) a history of surgery
for complex obesity, iii) large abdominal ventral hernia,
iv) Crohn’s disease, v) liver cirrhosis and portal hyper-
tension, vi) systemic lupus erythematosus, vii) known
silicone allergy and viii) participants who are pregnant
(women who have given birth and women planning
pregnancy will NOT be excluded). We will also record
specific reasons where surgeons are unwilling to random-
ise a patient.
All reasons for ineligibility will be recorded in the trial
screening log and where eligible patients decline ran-
domisation, we will ask for written consent to access
clinical records to collect baseline details, the type of
surgery performed and to invite them for one assess-
ment of weight and HRQOL at three years (the primary
endpoint). The screening log will be reviewed on a
monthly basis to provide feedback to recruiters since it
will help to understand surgeons’ and patients’ prefer-
ences for types of surgery. It will also allow the trial re-
sults to be reported in accordance with the CONSORT
guidelines.
All patients referred for bariatric surgery (100%)
Eligible for By-Band (60%)
168 randomised to:
84 Bypass 84 Band
n=800
n=480
n=168 (126 + 42)
Not eligible, 40%, n=320
Not recruited; 70% in first 18 
months, 50% thereafter, n=312
Phase 1, in 2 centres
All patients referred for bariatric surgery (100%)
Eligible for By-Band (60%)
556 randomised to:
278 Bypass 278 Band
n=3020
n=1812
Potential n=773
n=556 needed
Not eligible, 40%, n=1208
Not recruited, n=1039
50% in phase 1 centres, n=240
70% in new centres for 12 
months, n=466, and 50% in final
12 months, n=333
85% followed to primary outcome, n=614 
in primary analyses at 3 years 
Phase 1 & 2 patients (168 + 556) 
followed up after surgery, n=724
Phase 2, in 8 centres
Figure 1 Trial schema. Schema showing the number of patients to be recruited in Phase 1 (two centres) and Phase 2 (eight centres), with the
anticipated eligibility, recruitment and follow-up rates.
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given the patient information leaflet and an appointment
for a ‘recruitment consultation’. At that consultation they
will be given the opportunity to ask questions about the
study and treatments, and invited to participate in the
trial. These consultations, where consent is given, will
be routinely audio-recorded and form part of the quali-
tative study.
Randomisation
After trial eligibility has been confirmed and consent
given, randomisation will be carried out. This will be
usually within a week of gaining patient consent. A se-
cure Internet-based randomisation system will be usedensuring allocation concealment. The allocation will not
be revealed until participant details have entered into
the system. Participants will be allocated in a 1:1 ratio
and cohort minimisation (with a random element incor-
porated) will be used to ensure the groups are balanced
for diabetes (any type/none), and BMI (more than 50/50
or less). Allocation will also be stratified by centre.
Patients will be informed about their randomisation
arm as soon as possible and to allow them time to make
arrangements for support at home after discharge from
hospital (which is different between the two procedures)
and it will allow surgeons time to efficiently plan an
operating list (because of the time difference required in
theatre for each procedure). We have considered the risk
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and this will be monitored closely, but we are anticipat-
ing that with feedback from the qualitative research, the
recruitment process will have created equipoise among
participants.
Integrated qualitative research
The integrated qualitative study aims to understand the
recruitment process and work with study staff to put any
necessary changes in place to optimise this. The process of
recruitment will be explored using the following methods
based on previous work by Donovan et al. [24]:
(a) Patient pathway through eligibility and recruitment:
a comprehensive process of logging of potential
RCT participants through screening and eligibility
phases will be used to monitor recruitment. Flow
charts will be produced to show the degree of
complexity of participation and any variations
between centres.
(b) In-depth semi-structured interviews to understand
perspectives of participation will be conducted with
three groups:
i) Members of the trial management group (TMG),
including the chief investigator (CI) and those
most closely involved in the design, management,
leadership and coordination of the trial;
ii) Clinical and recruitment staff at the participating
centres;
iii)Eligible participants, including those who agree or
decline to take part. Interview topic guides based
on guides used in previous trials [24-26] will be
used to ensure similar areas are covered in each
interview within each group, but also encouraging
the informants to express their own views about
the RCT and any recruitment challenges expected
or experienced.
Interviews will be audio-recorded and transcribed
and analysed thematically using techniques of con-
stant comparison and case-study approaches
[24,25]. Interviews will provide data about: the per-
spectives of eligible patients; the evidence under-
lying the RCT, including the importance of the
question and the commitment of staff to it, as well
as individual clinical equipoise; the application of
the protocol in clinical centres and any logistical
issues; and suggestions about reasons for recruit-
ment difficulties and potential solutions from those
working closely within the RCT.
(c) Audio-recording of recruitment appointments: all
staff involved in providing information about the
RCT will be requested to audio-record appointments
where they provide information to patients and
attempt to recruit them to the RCT.Audio-recordings of appointments will be
transcribed verbatim whole or in selected parts, as
necessary for analysis. Appointments will be
analysed thematically and with the techniques of
focussed conversation analysis - pioneered in
previous studies [24] - to identify and document
aspects of informed consent and information
provision that are unclear, disrupted or hinder
recruitment. Recordings will be listened to by JLD
and SP only. An assessment will be made as to
whether the appointment is recruiter or
participant-led, and also the degree to which there
is evidence that the participant has understood
the key issues of equipoise, randomisation,
participation in the RCT, the option to choose
their treatment, and the option to withdraw from
the research at any time. These data will form the
basis for feedback to individuals and to determine
the content of the information, and training
programmes to be initiated in Phase 2 of the RCT.
(d) Non-participant observation of staff-patient
interactions: observations of clinics such as the
‘one-stop’ and pre-assessment clinics and
‘information days’ will be undertaken with
consent. The aim of the observations will be to
provide additional information about the
recruitment process.
Implementation of qualitative findings
The qualitative researcher (SP) will undertake the data
collection for (a) to (d) in each clinical centre, and lead
the analysis of the data with supervision and assistance
from the qualitative study lead (JLD). Data will be ana-
lysed first after approximately two months of active re-
cruitment and the key anonymised findings from each of
(a) to (d) presented to the CI and staff in the clinical
centre, with confidential feedback also provided to indi-
vidual recruiters. Selected relevant findings from (a) to
(d) will be used to develop a ‘plan of action’ with the CI
and principal investigators (PIs) to improve recruitment
and determine further data collection and analysis to
evaluate the implementation of the plan. This cycle will
be repeated as required. Aspects of the ‘plan’ in other
similar trials Recruitment will be up-dated regularly and
any changes noted. Issues discussed in other studies in-
cluded streamlining patient pathways, removing logis-
tical barriers, and improving the presentation of generic
and specific study information [25]. Minutes of meetings
will document salient recruitment issues, and these and
recruitment levels, will be discussed at TMG meetings.
Progression from Phase 1 to Phase 2
The criteria for progression to the full trial will be
reviewed at 18 months after recruitment has started.
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ric surgery to be eligible for the trial (if necessary revising
the eligibility criteria), ii) 50% consent to randomisa-
tion, iii) < 5% failure to receive allocated treatment, and,
iv) < 5% lost to follow-up (average duration of follow-up
will be nine months at this point). In addition, a review of
the literature regarding sleeve gastrectomy and a review of
current UK practice of sleeve gastrectomy will be under-
taken to understand whether uptake and standardisation
of the procedure is sufficient to extend the study in Phase
2 to include a third treatment arm.
Trial interventions
Wherever possible, after randomisation, participants
will be listed for surgery within 18 weeks of referral for
surgery, unless specifically requested by the participant
for personal reasons. The protocol for the surgery is
pragmatic. Both surgical procedures will be performed
laparoscopically under general anaesthesia with all pa-
tients receiving antibiotic and deep vein thrombosis
prophylaxis.
Laparoscopic adjustable gastric banding (Band surgery)
The procedure will involve placement of laparoscopic
ports, creation of a pneumoperitoneum and placement
of retractors as the surgeon chooses. The choice about the
type and size of adjustable gastric band will be made by
the surgeon. If a hiatal defect is present it will be repaired
and this recorded. Closure of a pre-existing umbilical her-
nia or concomitant cholecystectomy will be carried out at
the discretion of the surgeon and recorded. It is consid-
ered mandatory to dissect the lesser curve using the ‘pars
flaccida’ technique, to use gastro-gastric tunnelling sutures
and to fix the port to the anterior abdominal wall. An
apronectomy is prohibited.
Laparoscopic gastric bypass surgery (Bypass surgery)
The laparoscopic ports, creation of a pneumoperitoneum
and placement of retractors may be performed as the
surgeon chooses. Creation of the biliary and gastric limbs
and formation of the gastric pouch is performed as the
surgeon chooses. Upper limits of 75 cm and 150 cm are
recommended for the biliary and gastric limbs, respect-
ively. Testing integrity of the anastomoses, closure of a
pre-existing umbilical, internal hernia or hiatal hernia de-
fect or concomitant cholecystectomy will be carried out at
the discretion of the surgeon and recorded. Formation of
a horizontal gastric pouch that includes the fundus and
undertaking an apronectomy are prohibited.
After surgery, patients will be nursed within a specialist
ward and oral intake commenced according to the local
policy and at the surgeon’s discretion. The day of dis-
charge will be at the surgeon’s discretion. In both groups,the use of naso-gastric tubes, central lines, urinary cath-
eter and post-operative contrast swallow is optional.
Complications of surgery
Any major surgery involves the potential for complica-
tions; some are common to all abdominal operations,
while others specific to bariatric surgery. Complications
of abdominal surgery include infection, venous thrombo-
embolism, haemorrhage, hernia and bowel obstruction
(often many years after surgery).
A commonly reported complication of Band surgery is
regurgitation. Other complications include ulceration; gas-
tritis; erosion causing the band to slowly migrate through
the stomach wall; slippage (rare); malposition of the band
(rare with experienced practitioners); problems with the
port and/or the tube connecting port and band; internal
bleeding and infection.
Complications of Bypass surgery include anastomotic
leak; anastomotic stricture; anastomotic ulcer and dump-
ing syndrome. Bypass surgery can also lead to nutritional
deficiencies. Patients are required to follow the surgeon’s
instructions for food consumption, including the number
of meals to be taken daily, adequate protein intake, and
the use of vitamin and mineral supplements. Calcium
supplements, iron supplements, protein supplements,
multi-vitamins and vitamin B12 supplements are all
very important to the post-operative Bypass patient.
Study centres and surgeons
All centres will be surgical units carrying out at least 50
bariatric surgery operations per year and will have carried
out a minimum of 250 Bypass and 250 Band procedures
before entering patients into the trial. Participating sur-
geons will work within a specialist multi-disciplinary
bariatric team with at least two surgeons. Phase 1 will
take place in two UK centres. In Phase 2 recruitment
will be extended into up to six more centres. Participating
surgeons will have performed more than 100 laparoscopic
Bypass procedures and more than 50 laparoscopic Band
procedures for complex obesity.
Quality control of surgery and follow-up appointments
Procedures will be video or digitally recorded and up to
10% sample of anonymised operations will be reviewed
to ascertain adherence to mandatory and prohibited as-
pects of the surgery protocols. During Phase 1, a manual
will be developed describing all the core mandated com-
ponents of the surgical procedures, concomitant inter-
ventions and context and describe acceptable deviations
(that is components that can be flexibly delivered) as
well as those that are considered prohibited (unaccept-
able), as outlined above. This manual will then be used
in Phase 2 to monitor quality control, fidelity to proced-
ural steps, errors and near miss events. It is anticipated
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lised’ may include type of anaesthesia, and key elements
of recovery pathways such as analgesia or intravenous
fluid regimes.
Follow-up consultations will be according to specific
protocols. This will be performed by a trained research
nurse or surgeon. The patient will be interviewed by the
research nurse to assess the amount of food they are
able to eat, their appetite and whether they feel satisfied
between meals. They will receive support and advice.
For patients in the Band arm, if a fill is indicated, it will
be carried out according to the local protocol and the
patient will be tested for restriction. If there is too much
restriction, fluid will be withdrawn. The band is filled
progressively to reach the so-called ‘sweet spot’ of opti-
mal restriction. Care is taken to try to avoid over-filling
the band at any one time to avoid the problem of the
need to withdraw fluid from the band urgently. Occa-
sionally the port may not be accessible in the clinic and
filling of the band may need to be done under X-Ray
control. When this occurs it will be separately docu-
mented. However, fixing the port to the rectus sheath
usually avoids the need to do this.
Participants in the Bypass arm will undergo similar
supportive educational consultations performed by a
trained research nurse or physician to help support and
maintain a reduction in food intake and an increase in
activity level. All patients will be interviewed about nutri-
tional habits and behaviour and assessments of nutritional
status performed in line with the American Association
of Clinical Endocrinologists (AACE) guidelines [27].
Deficiencies identified will be treated and investigated in
line with these guidelines. Persistent nausea, vomiting,
dysphagia, ingestion, insufficient weight loss or weight
gain will promote further investigation and additional
reviews.
Primary outcomes
There are two primary endpoints, i) the proportion of
patients achieving a loss of greater than 50% of excess
weight at three years, calculated as:
100  BMIat threeyears‐BMIat randomisation½ =
BMIat randomisation‐25½ 
and ii) HRQOL at three years (EQ-5D health state score).
BMI at baseline will be calculated using the participant
weight recorded at baseline, after consent and before ran-
domisation. The participants’ weight in kilograms (kg) will
be measured on calibrated electronic clinic scales. Partici-
pants will be weighed fully clothed after removal of shoes,
jackets and heavy items from pockets. Participants will
stand with weight evenly balanced on both feet with their
arms hanging loosely at their sides. Participants’ heaviestweight ever (both self-reported and the heaviest recorded
in the participants’ medical records) will also be collected.
Participants’ height at randomisation will be measured in
centimetres with a calibrated stadiometer after removal of
shoes.
The dual endpoint was chosen after careful consider-
ation and discussion. It was chosen to be clinically mean-
ingful to patients, surgeons and commissioners, that is
combining effective weight loss with improved HRQOL.
This is, however, a difficult area as there is no universally
accepted definition of success (or failure) amongst pa-
tients having bariatric surgery and clinically meaningful
improvements of quality of life and co-morbidity (for
example, reductions in diabetes and sleep apnoea) can
be achieved with as little as 20% total body weight loss
[28]. In order to discriminate small differences between
procedures in a way that will usefully inform the treat-
ment choices, we wanted to set a criterion that would
represent successful weight loss for the majority of pa-
tients. Therefore, we reviewed historic excess weight
loss data for the two operations after three years for the
lead site and chose 50% because this lay towards the
‘tail’ of the distribution, that is only 20% of patients
experienced less than 50% excess weight loss.
Secondary outcomes
These will include:
i) BMI over time adjusted for BMI at randomisation,
ii) percentage weight loss at three years:
½ weight at randomisation‐weightat three yearsð Þ=
weight at randomisation
iii)waist circumference at three years,
iv) time taken from randomisation to reach first loss of
at least 50% of excess BMI,
v) time taken from first losing 50% excess BMI to first
relapse (defined as weight re-gain such that the tar-
get of at least 50% of excess weight loss is no longer
met),
vi) generic and symptom specific HRQOL to three years,
vii) resource use to three years,
viii) standard nutritional blood tests performed at each
assessment including; full blood count, electrolytes,
creatinine, glucose, HbA1c, liver function tests, iron,
ferritin, vitamin B12, folate/red cell folate, lipid profile,
25-hydroxyvitamin D, calcium, parathyroid hormone,
ix)measures of 24-hour recall dietary intake using a
standardised and validated interview process,
x) binge eating behaviour using a validated questionnaire,
xi) harms of surgery including peri-/post-operative
complications, the need for re-operation and cross
over between interventions,
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sleep apnoea, non-alcoholic fatty liver disease, type-2
diabetes, hypertension and hyperlipidaemia, and
xiii) time to resolution of sleep apnoea, type-2 diabetes,
hypertension and hyperlipidaemia.
Assessment of secondary outcomes
The generic and disease specific measures include as-
sessments with the SF12, EQ-5D [23], the Impact of
Weight of Quality of Life-Lite (IWQOL-Lite) question-
naire [29,30], the Gastrointestinal Quality of Life Index
(GIQLI, 36 items) [31], and the Hospital Anxiety and
Depression Scale (HADS) [32]. Questionnaires adminis-
tered at baseline before randomisation will be given to pa-
tients to complete themselves when they attend hospital.
Questionnaires completed after surgery will be posted to
participants by the coordinating centre to ensure that the
follow-up time points are met. An option to log in to a se-
cure web-site and complete the questionnaires on-line will
also be provided. Reasons for the non-completion of ques-
tionnaires will be recorded. Missing or erroneous items on
questionnaire measures will be handled according to the
questionnaire developers’ scoring manuals. Reasons for
withdrawal from the study, loss to follow-up or death (and
cause of death) will be recorded. The dietary intake recall
will be measured by trained research nurses, using repeat
24-hour recalls at baseline and single 24-hour recalls at
all follow-up assessments. Sleep apnoea will be assessed
using the STOP-BANG questionnaire at baseline and the
Epworth Sleepiness Scale, completed at baseline and
each research follow-up assessment [33]. Patients will
be selected for sleep studies on the basis of history or a
score of 5 or more using the STOP-BANG question-
naire [33]. An exploratory assessment of non-alcoholic
fatty liver disease will be made at baseline and three
years using the enhanced liver fibrosis test (ELF) [34].
Assessment of co-morbidities
Resolution of co-morbidities will be assessed with the
agreed definitions; resolution of obstructive sleep apnoea
will be defined after repetition of sleep studies. The
standard definition is less than five apnoea episodes per
hour as assessed by polysomnography (sleep study). Re-
mission of diabetes will be defined by criteria set out
from a consensus meeting in Diabetes Care for remis-
sion after surgery [35] and HbA1c, fasting glucose and
number of diabetes medications taken will be recorded at
follow-up appointments. Remission is defined as achieving
glycaemia below the diabetic range in the absence of
active pharmacologic (anti-hyperglycaemic medications,
immunosuppressive medications) or surgical (on-going
procedures such as repeated replacements of endoluminal
devices) therapy. A remission can be characterized as
partial or complete. Partial remission is sub-diabetichyperglycaemia (A1c not diagnostic of diabetes (<6.5%),
fasting glucose 100 to 125 mg/dl (5.6 to 6.9 mmol/l)) of at
least one year’s duration in the absence of active pharmaco-
logic therapy or on-going procedures. Complete remission
is a return to ‘normal’ measures of glucose metabolism
(A1c) in the normal range, fasting glucose < 100 mg/dl
(5.6 >mmol/l)) of at least one year’s duration in the ab-
sence of active pharmacologic therapy or on-going proce-
dures. Remission from hypertension will be based on the
international definition described in the metabolic syn-
drome, systolic blood pressure < 130 mmHg and diastolic
< 85 mmHg without treatment. Standard remission of
hyperlipidaemia will be defined as total cholesterol ≤
5.0 mmol without cholesterol lowering treatments. We
will also record the time to resolution of sleep apnoea,
type-2 diabetes, hypertension and hyperlipidaemia. A
20 ml blood sample will also be taken at baseline and at
three years for future investigations. The data collection
schedule is summarised in Table 1.
Assessment of resource use
The economic evaluation will follow established guidelines
[36,37]. The main outcome measure will be quality adjusted
life years (QALYs) using EQ-5D [23], to be administered at
baseline, four weeks, six and 12 months and then at annual
follow-up. Respondents will be assigned valuations derived
from published UK population tariffs [38] and the mean
number of QALYs per trial arm and incremental QALYs
will be calculated. Data on percentage weight loss will act
as an additional outcome measure. Data will be collected
from the trial centres on health care resource use for sur-
gery, follow-up appointments and treatments for any side
effects. The costs for short term surgical complications
such as peri-operative injury to adjacent organs and early
post-operative morbidities such as staple leak or bleed will
be estimated. The costs of longer term complications such
as wound hernias, or the need for re-intervention or for
cosmetic plastic surgery will be recorded.
Resource use will be measured in naturally occurring
units; for example, staff time will be measured in terms
of length of times for treatments and unit costs will be
derived from nationally published sources where avail-
able and from trial centres. Collection of these details
will allow micro-costing of the two surgical strategies.
This is important information that we have identified as
lacking, which can feed into NHS tariffs. Costs for con-
tact with additional health care professionals as a result
of surgery such as GP visits will be estimated.
Participant follow-up
Follow-up will take place at four weeks, three, six, nine,
12, 24 and 36 months after surgery. Research data col-
lection will not be required at the nine-month visit.
Participants may have additional consultations outside
Table 1 Data collection at the standard assessments
Pre randomisation Post randomisation
Day of surgery 4 weeks
Months
3 6 12 24 36
Weight X X X X X X X X
Height X
Blood pressure X X X X X X X
Waist circumference X X X X X X X
SF12 X X X X X X
EQ-5D X X X X X X
IWQOL-Lite X X X X X X
GIQLI X X X X X X
HADS X X X X X X
Resource use questionnaires X X X X X X X
Nutritional blood testsc
Full blood count X X X X X X
Electrolytes X X X X X X
Creatinine X X X X X X
Fasting glucose X X X X X X
Lipids X X X X X X
HbA1c X X X X X X
Liver function tests X X X X X X
Iron, ferritin, vitamin B12 X X X X X X
Folate/red cell folate X X X X X X
Lipid profile X X X X X X
25-hydroxyvitamin D X X X X X X
Calcium X X X X X X
Parathyroid hormone X X X X X X
Blood sample for future research X X
24-hour recall eating questionnaire X X X X X X
Binge eating questionnaire X X X X X X X
Other co-morbidity
Sleep apnoea
STOP-BANG X
Epworth sleepiness scale X X X X X X
Non-alcoholic fatty liver diseaseb X X
National bariatric surgery registry X X X X X
In-depth interviewsa X X X X X X X
Table showing data and blood samples collected at different stages of the participant’s pathway through the trial (X = data or sample collected).
aundertaken in a purposeful sample of participants.
benhanced liver fibrosis test.
cfor the assessment of co-morbidities.
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requirements (expected to be up to ten appointments
in the first two years). Active participation in the trial
ends at 36 months. Thereafter, participants will be
followed through the ‘Medical Research Information
Service’ (NHS Information Centre) for mortality; theparticipant’s weight will be requested from the hospital
on an annual basis.
Sample size
The study size has been set at 614; allowing for a 15%
loss to follow-up at three years, the target sample size is
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hypotheses that (a) Bypass will be non-inferior to Band in
terms of the proportion of participants achieving an excess
weight loss of at least 50% at three years and that (b) the
HRQOL at three years for participants receiving a Bypass
will be superior to the HRQOL for participants with a
Band. The significance level for the non-inferiority hy-
pothesis was set at 2.5% (one-sided) and for the superiority
hypothesis it was set at 5% (two-sided).
The power calculation for the first hypothesis requires
the estimation of two parameters, i) the total proportion
of participants that are expected to have lost at least
50% of their excess weight at three years and ii) the dif-
ference in proportions achieving this target that would
be considered clinically important (the non-inferiority
margin). In By-Band it was assumed that 70% of patients
will have lost ≥ 50% of their excess weight at three years
and that a difference of ≥ 12% between the groups would
be clinically important. The expected proportion of partic-
ipants losing at least 50% of their excess weight at three
years was estimated from the Taunton local database; for
the sub-group with a BMI at surgery of between 40 and
60, 73% of Band and 75% of Bypass patients had lost at
least 50% of their excess weight at three years. The non-
inferiority margin was chosen on the basis of the opinions
of the clinical team members and patient representatives.
The power calculation for the second HRQOL hypoth-
esis, which for simplicity assumes the data will be analysed
using analysis of covariance, requires the estimation of six
parameters, the within group standard deviation, the differ-
ence in mean HRQOL that would be considered clinically
important, the number of pre and post-surgery measures,
and the correlations between pre and post-surgery scores
and between repeated post-surgery scores. The estimates
used were chosen on the basis of the published literature
[39,40] and, in order to estimate correlations between
different time points, on data from a surgical trial on spine
injury. It was assumed that a small difference in mean
HRQOL of 0.2 standard deviations would be clinically im-
portant. Conservative estimates of the correlation between
repeated measures have been assumed (0.5 between pre
and post measures, 0.75 between repeated post measures).
The calculation is based on three post-surgery measures
and assumes the treatment difference is similar at the
three time points. However, the difference in HRQOL
between groups may change over time. The calculation
based on a single measure shows that the study will have
80% power to detect differences at individual time points.
The sample size was calculated using Stata version 12.1
(Stata Corp LP, College Station, TX, USA).
Statistical analyses
The analyses of the quantitative trial data will be based
on intention-to-treat and will include all randomisedpatients. For the non-inferiority hypothesis a per-
protocol analysis will also be carried out. Analyses will be
adjusted for design factors included in the cohort mini-
misation. The proportion of patients with at least 50% ex-
cess weight loss at three years will be compared using
mixed effects logistic regression. HRQOL scores (and
other continuous outcomes measured at multiple time
points) will be compared using a mixed linear regression
model with baseline and post-surgery measures modelled
jointly. Changes in treatment effect with time will be
assessed by adding a treatment-by-time interaction to the
model and comparing models with and without the inter-
action using a likelihood ratio test. Time-to-event out-
comes will be compared using survival methods for
interval censored data. Model fit will be assessed and alter-
native models and/or transformations (for example, to in-
duce normality) will be explored where appropriate.
Frequencies of adverse events will be described. Treat-
ment differences will be reported with 95% confidence in-
tervals. There is no intention to compare any outcomes
between groups after Phase 1; the only analyses will be
descriptive statistics to summarise recruitment to de-
cide whether the trial satisfies the progression criteria.
The surgeon is not considered when randomly allocat-
ing participants to Bypass or Band as randomisation takes
place 18 weeks before surgery. However, the allocation is
stratified by centre and we will take the data structure into
account, that is nesting of patients by surgeon and centre,
in the primary analyses. One subgroup analysis is planned;
outcomes will be described for patients with and without
diabetes mellitus at baseline. Differences in treatment ef-
fect between the two subgroups will be tested by including
an interaction term in the analysis model. This is a sec-
ondary analysis as the study is not powered to detect
subgroup differences.
The health economic analysis will calculate the average
cost and outcome on a per patient basis and, from this
the incremental cost-effectiveness ratios for the different
trial arms will be derived, producing an incremental cost
per QALY and cost per percentage weight loss achieved.
Probabilistic sensitivity analysis will be used to demonstrate
the impact of the variation around the key parameters
in the analysis on the baseline cost-effectiveness results.
Results will be expressed in terms of a cost-effectiveness
acceptability curve, which indicates the likelihood that
the results fall below a given cost-effectiveness ceiling.
Decision modelling will be used to explore longer terms
costs and effects for at least 20 years post-surgery. This
will enable us to consider for instance longer term costs
such as vitamin B12 replacement, calcium and vitamin D
replacement for Bypass and follow-up for post-gastric sur-
gery bone disease. Also cost savings as a result of a poten-
tial reduction or resolution in co-morbidities (for example,
diabetes) will be explored.
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Minor changes have been made. The exclusion of pa-
tients with a large hiatus hernia has been removed be-
cause participating surgeons are prepared to repair the
hernia concurrently with the trial interventions. Post-
discharge follow-up was changed from six weeks to
four weeks on the recommendation of bariatric ex-
perts, to reflect the timing of the routine clinical
follow-up post-surgery and a three-month follow-up
was added for both groups. The Epworth sleepiness
scale and the HADS questionnaire were added to im-
prove assessment of secondary outcomes. Definition of
resolution of sleep apnoea was revised to exclude discon-
tinuation of the use of a continuous positive airways pres-
sure (CPAP) machine and patient report, on the advice of
the independent TSC. Recommended upper limits for the
biliary and gastric limbs were changed from 100 cm and
200 cm respectively to 75 cm and 150 cm, respectively.
Assessment of dietary intake at four weeks post-surgery
was removed because patients are required to go on a six-
week post-operative diet, so a four-week dietary recall is
not useful.
Development of a core outcome set to assess the benefits
and adverse outcomes of bariatric surgery (BARIACT)
During Phase 1 of By-Band, a core outcome set to define
the benefits and adverse surgical events will be developed
using similar methodology as used by the OMERACT
group [41]. The purpose of this is to ensure that future
trials in obesity surgery report at the very least the core
outcome set allowing for future evidence synthesis and
cross study comparisons, as well as reducing reporting
bias. Systematic literature reviews will identify all the
current reported clinical outcomes of bariatric surgery
(and their definitions). Outcomes reported by the National
Bariatric Surgery Registry will be included. Qualitative in-
terviews with surgeons and patients will identify additional
potential outcomes of importance that are not identified
from literature searches. Delphi methodology surveying
surgeons and patients will reduce the potential list to a
shorter list of outcomes to be discussed at the consensus
meetings. In the Delphi survey, stakeholders will be asked
to rate the importance of inclusion of each potential out-
come in the core outcome set and two rounds will be
undertaken to reduce the list according to pre-specified
criteria. Each Delphi round will be analysed to identify key
or redundant items from the list. A consensus meeting will
be convened with key stakeholders at the same time as a
TSC meeting to discuss the survey results and to perform
further anonymised rating of the importance of retained
items. The work will link with the COMET initiative and
the MRC ConDuCT Hub for trials methodology research
[42,43]. The final core set of outcomes of bariatric surgery
is expected to be fewer than ten items.Discussion
The By-Band study will examine the effectiveness and
cost-effectiveness of the two most commonly performed
surgical procedures for complex obesity. It has integrated
qualitative research to overcome the likely barriers to re-
cruitment related to surgeon and patient preferences [44].
The By-Band study, however, is an open surgical trial in
which participants, clinicians and other hospital staff car-
ing for participants will not be ‘blind’ to their allocation.
This is because of the need for adjustment of gastric bands
with injection of saline into the subcutaneous port. It was
considered too difficult to put in place an equivalent
‘sham’ procedure for participants having Bypass (given pa-
tients’ knowledge about the operations). Moreover, using a
sham control might have removed one of the influences
on HRQOL of Bypass, namely less intensive hospital
follow-up. The study, therefore, is at risk of bias, particu-
larly performance and detection bias [45]. The following
measures have been put in place to minimise the potential
for bias: i) concealed randomisation to protect against
selection bias, ii) standard protocols (and monitoring of
adherence) for follow-up after both procedures to min-
imise the risk of performance bias arising from carers
differentially providing co-interventions, iii) blinding of
the assessor undertaking measurements of all outcomes
at the primary endpoint (three years) to minimise detec-
tion bias; iv) other outcomes defined as far as possible
on the basis of objective criteria (for example, biochemical
markers will be measured by an independent laboratory
technician at the local hospital, without knowledge of
treatment allocation). Every effort to keep in touch with
participants (through annual assessment; checking on
change of address, and so on) will be made especially if a
participant misses an annual follow-up assessment to min-
imise attrition bias. The success of blinding will be tested
and reasons for unblinding recorded. Self-completion
HRQOL measures will inevitably be susceptible to bias
although expectations about any effects of the different
procedures prior to surgery are likely to be reduced
through optimising information given prior to surgery
(informed by the qualitative research) and it is expected
that these will wane with follow-up, so participants will
not have strong differential expectations of the treatments
after three years.
The joint hypothesis of non-inferior weight loss and
superior HRQOL with Bypass was chosen to reflect expert
opinion on the benefits and risks of the two procedures. It
is recognised that the weight loss profile is different for
the two procedures; there is rapid weight loss with Bypass,
which may be difficult to maintain in the longer term,
whereas with Band the weight loss is more gradual; obser-
vational data suggests at three years the excess weight loss
is comparable, hence the non-inferiority hypothesis. The
likelihood of longer term complications (such as the need
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Bypass and this is why it is hypothesised at three years
there will be superior HRQOL with Bypass.
The trial will be analysed on an intention-to-treat
basis, that is outcomes will be analysed according to the
treatment allocation, irrespective of future management
and events, and every effort will be made to include all
randomised participants. We recognise that a per-protocol
analysis is advocated for non-inferiority hypotheses and
we will also conduct an analysis by surgery received of the
proportion achieving at least 50% excess weight loss at
three years. However, we anticipate that cross-overs will
be few. A detailed statistical analysis plan will be prepared
in advance of any formal analysis of the study data, which
will be discussed with members of both the TSC and the
Data Monitoring and Safety Committee. Follow-up for the
outcome measures during the participant’s stay in hospital
should be complete for all participants.
In Phase 1, we will review practice and incidence of
sleeve gastrectomy as it is possible that this may have in-
creased since the start of the study. If so, consideration
will be given to incorporating sleeve gastrectomy into
the trial design by discussion with the funding body and
the TSC.
Trial status
The trial opened to recruitment in one centre in
November 2012 and in the other centre in February
2013. Interviews with the study teams have taken place,
consultations have been audio-recorded, analysed and the
results fed back to the study team. Trial participation has
increased following this feedback. Recruitment in the two
Phase 1 centres is on-going.
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